Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS

– Genzyme Pursuing Innovative Approaches for Investigational Treatments Targeting Relapsing and Progressive Forms of MS –

– More Than 25 Oral and Poster Presentations Reinforce the Breadth and Depth of Genzyme’s MS Clinical Development Programs –

CAMBRIDGE, Mass.–(BUSINESS WIRE)–

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30thCongress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) being held in Boston Sept. 10-13. The company will also present this week 26 oral and poster presentations from its MS franchise, including four-year results from the Lemtrada™ (alemtuzumab) extension study,12-year MRI data for Aubagio® (teriflunomide), and data from the Aubagio TOPIC study, which was recently published in The Lancet Neurology.

In addition to its marketed therapies, Genzyme has an MS R&D pipeline focused on investigational treatments to address unmet needs for relapsing and progressive forms of MS through research in selective immunomodulation, neuroprotection and remyelination.

Key Genzyme MS programs and collaborations in clinical and preclinical development include:

• Vatelizumab – An investigational anti-VLA-2 humanized monoclonal antibody currently in a Phase II trial for relapsing forms of MS, in partnership with Glenmark Pharmaceuticals.
• GZ402668 – A next-generation investigational anti-CD52 humanized monoclonal antibody currently approaching Phase I clinical development.
• Discovery and research programs evaluating agents promoting remyelination, as well as agents targeted at central nervous system innate immune cells to provide neuroprotection.
• Collaborations with academic medical centers such as Brigham and Women’s Hospital to identify correlative biomarkers of disease progression, and with Cleveland Clinic to explore strategies to address neurodegeneration, a hallmark of progressive MS.

“Since FDA approval of once-daily oral Aubagio two years ago, Genzyme has continued to advance the understanding and treatment of MS by addressing important unmet medical needs for people living with the disease. Between clinical trials and commercial use in more than 40 countries, approximately 30,000 patients have now been treated with Aubagio,” said Genzyme President and CEO David Meeker. “With Lemtrada, we have also made significant progress with approvals in more than 30 countries. With our differentiated marketed therapies and a varied pipeline focusing on innovative treatment approaches and underserved MS patients with progressive disease, we are uniquely positioned to bring long-term value to the MS community.”

Presentations on Aubagio and Lemtrada at ECTRIMS are as follows, along with information about Genzyme-sponsored activities.

READ MORE